Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Фитониринг в клинической практике
________________________________________________
Tsukanov AIu, Matveev EV. Phytoneering in clinical practice. Consilium Medicum. 2021;23(12):977–980.
DOI: 10.26442/20751753.2021.12.201328
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
В статье представлены 2 клинических случая применения растительного препарата Канефрон Н с целью профилактики цистита и обострения мочекаменной болезни – ситуаций, часто встречающихся в практике уролога.
Ключевые слова: рецидивирующий цистит, мочекаменная болезнь, растительные препараты, Канефрон Н
________________________________________________
The discovery of antibiotics almost 100 years ago seemed to have forever solved the issue of treating infectious diseases for humanity. However, the avalanche-like growth in antibiotic resistance requires the search for alternative methods of treatment, one of which is treatment with herbal products created according to the phytoneering concept. It is a technology that combines the enormous potential of medicinal plants (phyto) with the knowledge and methodology of modern pharmaceutical research (engineering). The article presents 2 clinical cases of the use of the herbal product Canephron N for the prevention of cystitis and acute urolithiasis – common disorders in the practice of a urologist.
Keywords: recurrent cystitis, urolithiasis, herbal products, Canephron N
2. Синякова Л.А. Инфекции нижних мочевыводящих путей у женщин –проблемы и ошибки. Урология. 2021;1:140-5 [Siniakova LA. Infektsii nizhnikh mochevyvodiashchikh putei u zhenshchin – problemy i oshibki. Urologiia. 2021;1:140-5 (in Russian)].
3. Цистит у женщин. Клинические рекомендации РОУ, 2021 [Tsistit u zhenshchin. Klinicheskie rekomendatsii ROU, 2021 (in Russian)].
4. Синякова Л.А. Профилактика рецидивирующих инфекций нижних мочевых путей. Consilium Medicum. 2013;15(6):44-6 [Sinyakova LA. Prevention of recurrent lower urinary tract infections. Consilium Medicum. 2013;15(6):44-6 (in Russian)].
5. Палагин И.С., Сухорукова М.В., Дехнич А.В., и др. Состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевыводящих путей в России, Беларуси и Казахстане: результаты многоцентрового международного исследования «Дармис-2018». Урология. 2020;1:19-31 [Palagin IS, Sukhorukova MV, Dekhnich AV, et al. Sostoianie antibiotikorezistentnosti vozbuditelei vnebol'nichnykh infektsii mochevyvodiashchikh putei v Rossii, Belarusi i Kazakhstane: rezul'taty mnogotsentrovogo mezhdunarodnogo issledovaniia “Darmis-2018”. Urologiia. 2020;1:19-31 (in Russian)].
6. Ivanov D, Abramov-Sommariva D, Moritz K, et al. An open label, noncontrolled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the managementof uncomplicated urinary tract infections (uUTIs). Clin Phytosci. 2015;1(7):1-11. DOI:10.1186/s40816–015–0008-x
7. Wagenlehner FM, Abramov-Sommariva D, Höller M, et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int. 2018;101(3):327-36. DOI:10.1159/000493368
8. Ny S, Edquist P, Dumpis U, et al. Antibiotic resistance of Escherichia coli from outpatient urinary tract infection in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25-34. DOI:10.1016/j.jgar.2018.11.004
9. Höller M, Steindl H, Abramov-Sommariva D, et al. Treatment of Urinary Tract Infections with Canephron® in Germany: A Retrospective Database Analysis. Antibiotics (Basel). 2021;10(6):685. DOI:10.3390/antibiotics10060685
10. Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol. 2013;5:39-46. DOI:10.2147/RRU.S39288
11. Аляев Ю.Г., Амосов А.В., Григорян В.А., и др. Применение растительного препарата Канефрона®Н у больных с хроническим циститом и мочекаменной болезнью. Урология. 2005;4:29-33 [Aliaev IuG, Amosov AV, Grigorian VA, et al. Primenenie rastitel'nogo preparata Kanefrona®N u bol'nykh s khronicheskim tsistitom i mochekamennoi bolezn'iu. Urologiia. 2005;4:29-33 (in Russian)].
12. Shoag J, Tasian GE, Goldfarb DS, Eisner BH. The new epidemiology of nephrolithiasis. Adv Chronic Kidney Dis. 2015;22(4):273-8. DOI:10.1053/j.ackd.2015.04.004
13. Sakhaee K, Maalouf NM, Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012;97(6):1847-60. DOI:10.1210/jc.2011-3492
14. Капсаргин Ф.П., Саенко В.С., Трояков В.М., и др. Роль растительных препаратов в литокинетической терапии и метафилактике мочекаменной болезни. Экспериментальная и клиническая урология. 2021;14(2):92-98 [Kapsargin FP, Saenko VS, Troiakov VM, et al. Rol' rastitel'nykh preparatov v litokineticheskoi terapii i metafilaktike mochekamennoi bolezni. Eksperimental'naia i klinicheskaia urologiia. 2021;14(2):92-98 (in Russian)].
15. Амосов А.В. Растительный препарат Канефрон в урологической практике. Врач. 2000;6:36 [Amosov AV. Rastitel'nyi preparat Kanefron v urologicheskoi praktike. Vrach. 2000;6:36 (in Russian)].
16. Григорян В.А., Амосов А.В., Султанова Е.А., и др. Применение Канефрона®Н при мочекаменной болезни. РМЖ. Урология. 2001;19(17):1113-6 [Grigorian VA, Amosov AV, Sultanova EA, et al. Primenenie Kanefrona®N pri mochekamennoi bolezni. RMZh. Urologiia. 2001;19(17):1113-6 (in Russian)].
________________________________________________
1. Kul'chavenia EV, Neimark AI, Tsukanov AIu, Iarin GIu. Sovremennye podkhody k diagnostike ostrogo tsistita i otsenke kachestva ego lecheniia. Urologiia. 2020;3:22-5 (in Russian).
2. Siniakova LA. Infektsii nizhnikh mochevyvodiashchikh putei u zhenshchin – problemy i oshibki. Urologiia. 2021;1:140-5 (in Russian).
3. Tsistit u zhenshchin. Klinicheskie rekomendatsii ROU, 2021 (in Russian).
4. Sinyakova LA. Prevention of recurrent lower urinary tract infections. Consilium Medicum. 2013;15(6):44-6 (in Russian).
5. Palagin IS, Sukhorukova MV, Dekhnich AV, et al. Sostoianie antibiotikorezistentnosti vozbuditelei vnebol'nichnykh infektsii mochevyvodiashchikh putei v Rossii, Belarusi i Kazakhstane: rezul'taty mnogotsentrovogo mezhdunarodnogo issledovaniia “Darmis-2018”. Urologiia. 2020;1:19-31 (in Russian).
6. Ivanov D, Abramov-Sommariva D, Moritz K, et al. An open label, noncontrolled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the managementof uncomplicated urinary tract infections (uUTIs). Clin Phytosci. 2015;1(7):1-11. DOI:10.1186/s40816–015–0008-x
7. Wagenlehner FM, Abramov-Sommariva D, Höller M, et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int. 2018;101(3):327-36. DOI:10.1159/000493368
8. Ny S, Edquist P, Dumpis U, et al. Antibiotic resistance of Escherichia coli from outpatient urinary tract infection in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25-34. DOI:10.1016/j.jgar.2018.11.004
9. Höller M, Steindl H, Abramov-Sommariva D, et al. Treatment of Urinary Tract Infections with Canephron® in Germany: A Retrospective Database Analysis. Antibiotics (Basel). 2021;10(6):685. DOI:10.3390/antibiotics10060685
10. Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol. 2013;5:39-46. DOI:10.2147/RRU.S39288
11. Aliaev IuG, Amosov AV, Grigorian VA, et al. Primenenie rastitel'nogo preparata Kanefrona®N u bol'nykh s khronicheskim tsistitom i mochekamennoi bolezn'iu. Urologiia. 2005;4:29-33 (in Russian).
12. Shoag J, Tasian GE, Goldfarb DS, Eisner BH. The new epidemiology of nephrolithiasis. Adv Chronic Kidney Dis. 2015;22(4):273-8. DOI:10.1053/j.ackd.2015.04.004
13. Sakhaee K, Maalouf NM, Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012;97(6):1847-60. DOI:10.1210/jc.2011-3492
14. Kapsargin FP, Saenko VS, Troiakov VM, et al. Rol' rastitel'nykh preparatov v litokineticheskoi terapii i metafilaktike mochekamennoi bolezni. Eksperimental'naia i klinicheskaia urologiia. 2021;14(2):92-98 (in Russian).
15. Amosov AV. Rastitel'nyi preparat Kanefron v urologicheskoi praktike. Vrach. 2000;6:36 (in Russian).
16. Grigorian VA, Amosov AV, Sultanova EA, et al. Primenenie Kanefrona®N pri mochekamennoi bolezni. RMZh. Urologiia. 2001;19(17):1113-6
(in Russian).
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*autt@mail.ru
________________________________________________
Anton Iu. Tsukanov*, Evgenii V. Matveev
Omsk State Medical University, Omsk, Russia
*autt@mail.ru